Ortho-mcneil Pharmaceutical Corp.

Janssen Pharmaceutica Nv

University of Utah Research Foundation

Other

Sk Biopharmaceuticals Co., Ltd.

Roy E Twyman

Boyu Zhao

Andrés Avelino Trabanco-Suárez

Brian D Klein

H Steven White

Robert T Gordon

Yong Moon Choi

Hilde Lavreysen

Stefan Maria Christiaan Pype

Roger Francis Bone

Jose Maria Cid-Nunez

Carlos Plata-Salaman

José Maria Cid-Núñez

Marc André Ceusters

H Steve White

Nancy Eulalie Sylvain Van Osselaer

Scott W Rogers

Lorise C Gahring

Carlos R Plata-Salaman

Gerald P Novak

Marc Andre Ceusters

Stefan Maria Pype

Nancy Eulalie Van Osselaer

Robert Gordon

The present invention relates to combinations comprising a positive allosteric modulator ('PAM') of metabotropic glutamatergic receptor subtype 2 (“mGluR2”) or a pharmaceutically acceptable salt or a solvate thereof, or an orthosteric agonist of metabotropic glutamatergic receptor subtype 2 compound or a pharmaceutically acceptable salt or a solvate thereof, and a synaptic vesicle protein 2A (“SV2A”) ligand.

Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use

The present invention relates to combinations comprising a positive allosteric modulator ('PAM') of metabotropic glutamatergic receptor subtype 2 ('mGluR2') or a pharmaceutically acceptable salt or a solvate thereof, or an orthosteric agonist of metabotropic glutamatergic receptor subtype 2 compound or a pharmaceutically acceptable salt or a solvate thereof, and a synaptic vesicle protein 2A (&#x201c;SV2A&#x201d;) ligand.

This invention is directed to a method for preventing or treating bipolar disorder comprising administering to a subject in need thereof a therapeutically effective amount of an enantiomer of Formula (I) or enantiomeric mixture wherein one enantiomer of Formula (I) predominates: wherein phenyl is substituted at X with one to five halogen atoms selected from the group consisting of fluorine, chlorine, bromine and iodine; and, R, R, Rand Rare independently selected from the group consisting of hydrogen and C&#x2013;Calkyl; wherein C&#x2013;Calkyl is optionally substituted with phenyl (wherein phenyl is optionally substituted with substituents independently selected from the group consisting of halogen, C&#x2013;Calkyl, C&#x2013;Calkoxy, amino, nitro and cyano).

Carbamate compounds for use in preventing or treating bipolar disorder

This invention is directed to a method for preventing or treating anxiety disorders comprising administering to a subject in need thereof a therapeutically effective amount of a compound selected from the group consisting of Formula (I) and Formula (II):wherein phenyl is substituted at X with one to five halogen atoms selected from the group consisting of fluorine, chlorine, bromine and iodine; and, R, R, R, R, Rand Rare independently selected from the group consisting of hydrogen and C-Calkyl; wherein C-Calkyl is optionally substituted with phenyl (wherein phenyl is optionally substituted with substituents independently selected from the group consisting of halogen, C-Calkyl, C-Calkoxy, amino, nitro and cyano).

Carbamate compounds for use in preventing or treating anxiety disorders

Carbamate compounds for use in the treatment of pain

Carbamate compounds for use in preventing or treating movement disorders

Carbamate compounds for use in preventing or treating psychotic disorders

A peptide containing 24 amino acid residues that binds to anti-neuronal-glutamate-receptor autoantibodies associated with Rasmussen's encephalitis and that blocks activation of the GluR3 subunit is described. Methods of making the peptide and treating Rasmussen's encephalitis are also disclosed. Autoantibodies to other glutamate receptor subunits are associated with paraneoplastic neurodegenerative disease, amyotrophic lateral sclerosis, and neurodegenerative disease of unknown diagnosis. Methods of screening patients and of monitoring patients being treated for these disorders and syndromes are further described.

Autoantibodies to neurotransmitter receptors

Peptide for blocking autoantibody-evoked activation of glutamate

Growing community of inventors

Doylestown, PA, United States of America

Roy E Twyman